Tetrahydrobiopterin and cardiovascular disease.
Tetrahydrobiopterin (BH4) is an essential cofactor for the aromatic amino acid hydroxylases, which are essential in the formation of neurotransmitters, and for nitric oxide synthase. It is presently used clinically to treat some forms of phenylketonuria (PKU) that can be ameliorated by BH4 supplementation. Recent evidence supports potential cardiovascular benefits from BH4 replacement for the treatment of hypertension, ischemia-reperfusion injury, and cardiac hypertrophy with chamber remodeling. Such disorders exhibit BH4 depletion because of its oxidation and/or reduced synthesis, which can result in functional uncoupling of nitric oxide synthase (NOS). Uncoupled NOS generates more oxygen free radicals and less nitric oxide, shifting the nitroso-redox balance and having adverse consequences on the cardiovascular system. While previously difficult to use as a treatment because of chemical instability and cost, newer methods to synthesize stable BH4 suggest its novel potential as a therapeutic agent. This review discusses the biochemistry, physiology, and evolving therapeutic potential of BH4 for cardiovascular disease.
Moens
An L
AL
Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, 720 Rutland Avenue, Baltimore, MD 21205, USA.
Kass
David A
DA
D000818:Animals; D050197:Atherosclerosis / Q000209:etiology; D001682:Biological Availability; D001708:Biopterins / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000737:chemistry / Q000502:physiology / Q000627:therapeutic use; D001808:Blood Vessels / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006321:Heart / Q000187:drug effects; D006801:Humans; D019001:Nitric Oxide Synthase / Q000378:metabolism; D018384:Oxidative Stress / Q000502:physiology
D001708:Biopterins; D019001:Nitric Oxide Synthase; C003402:sapropterin